Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that results in widespread paralysis and shortened life. Recently, a naturally-occurring organic acid called creatine has gained attention as a potential therapy for ALS/MND. However, human trials have shown mixed results thus far. Therefore, we systematically reviewed all available clinical trial evidence as of October 2009 to determine if creatine benefits or harms people with ALS/MND. This review included three well-designed clinical trials involving a total of 386 participants receiving either creatine or placebo. Overall, creatine was well-tolerated with no serious side effects. Using various statistical methods, we found that creatine at a dose of 5 to 10 g per day did not improve ALS survival or slow ALS progression in any meaningful way. There was a hint that creatine may slightly worsen breathing ability, but this may have just been misleading statistical variability.
Creatine for amyotrophic lateral sclerosis/motor neuron disease
Have your say!
'Your views on The Cochrane Library: survey'
Published Online:
August 8, 2010
More like this
- Antioxidants for treating amyotrophic lateral sclerosis
- Riluzole for amyotrophic lateral sclerosis (ALS)/ motor neuron disease (MND)
- We found no evidence of any beneficial effect of amino acid therapy (branched-chain amino acids or L-threonine) on amyotrophic lateral sclerosis / motor neuron disease
- Treatment for familial amyotrophic lateral sclerosis
- A single trial of moderate intensity endurance type exercise for spasticity in people with amyotrophic lateral sclerosis was too small to determine whether it was beneficial or harmful
